|1.||Chazot, Paul L: 1 article (07/2007)|
05/01/1986 - "This opinion is strengthened if one considers the subgroup of patients aged less than or equal to 25 years in which a statistically significant reduction in seizure frequency was observed with milacemide treatment. "
08/01/1984 - "Further, large doses of CP 1552-S appeared to result in paradoxical post-afterdischarge and possibly prestimulation electrical seizure activity."
08/01/1984 - "Against kindled amygdaloid seizures, CP 1552-S significantly reduced the duration of afterdischarge at 300 mg/kg (i.p.) without modifying the seizure and without prestimulation behavioral or electrical effects. "
08/01/1984 - "Large doses (300-600 mg/kg, i.p.) of CP 1552 given 30 min before stimulation resulted in significant reductions in duration of afterdischarge after both partially-developed and fully-developed cortically-kindled seizures. "
12/01/1983 - "Milacemide is particularly effective in inhibiting the convulsions induced by bicuculline. "
|2.||Alzheimer Disease (Alzheimer's Disease)
04/01/1993 - "A multicenter, double-blind, placebo-controlled, parallel group study was conducted to assess the safety and efficacy of three doses of milacemide in the treatment of patients with senile dementia of the Alzheimer type of mild to moderate severity. "
05/01/1992 - "Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type."
01/01/1991 - "Trials of milacemide in doses ranging from 400-1,200 mg once daily in Alzheimer's disease (AD) for 4 weeks have been disappointing, but milacemide has increased the accuracy and speed of word retrieval in human volunteers. "
04/01/1993 - "Evaluation of multiple doses of milacemide in the treatment of senile dementia of the Alzheimer's type."
05/01/1992 - "Milacemide, a MAO-B inhibitor that is also a prodrug for glycine, was tested as a treatment for senile dementia of the Alzheimer type (SDAT) because of its potential for enhancing cognition in animal models of impaired learning and memory. "
|3.||Myoclonus (Nocturnal Myoclonus)
04/01/1989 - "Milacemide may have potential for therapeutic trials in patients with myoclonus."
10/01/1993 - "Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders."
01/01/1991 - "We investigated the therapeutic effects of milacemide in seven patients with myoclonus and three patients with the stiff-person syndrome in an open-label trial. "
01/01/1991 - "A therapeutic trial of milacemide in myoclonus and the stiff-person syndrome."
04/01/1989 - "Milacemide, a glycine prodrug that is able to enter the brain readily, has been shown to have an antimyoclonic property in the p,p'-DDT-induced myoclonus syndrome. "
|4.||Schizophrenia (Dementia Praecox)
06/01/1991 - "In a prior study, "high-dose" milacemide proved to have no therapeutic utility in schizophrenia. "
08/01/1990 - "An open-label trial of milacemide in schizophrenia: an NMDA intervention strategy."
06/01/1991 - "Despite our negative findings for milacemide, other strategies for facilitating NMDA-mediated neural transmission in schizophrenia might be worth pursuing."
06/01/1991 - "An NMDA intervention strategy in schizophrenia with "low-dose" milacemide."
06/01/1991 - "Based on a proposed "glutamatergic deficiency" in schizophrenia, pharmacologic facilitation of NMDA-mediated neural transmission by direct stimulation of the strychine-insensitive glycine binding site was attempted with "low-dose" milacemide, an acylated "prodrug" of glycine that readily crosses the blood brain barrier and is converted into glycine in the brain. "
|5.||Stiff-Person Syndrome (Stiff Man Syndrome)
|1.||Glycine (Aminoacetic Acid)
|2.||Dizocilpine Maleate (Dizocilpine)
|4.||Monoamine Oxidase (MAO)
|8.||Glutamic Acid (Glutamate)
|10.||Levodopa (L Dopa)